Final Results - Part 3 of 3

AstraZeneca PLC
27 January 2005


                           AstraZeneca Development Pipeline: NCEs and line extensions
                                                 27 January 2005
Cardiovascular

NCEs

     Compound                Mechanism            Area under investigation     Phase        Estimated Filing
                                                                                            MAA           NDA

Exanta              thrombin inhibitor           prevention of VTE              III       Launched      Filed*

Exanta              thrombin inhibitor (s.c.)    prevention of VTE              III       Launched       >2007
SC formulation

Galida              PPAR agonist                 diabetes /metabolic            III         2007          2007
                                                 syndrome

AZD6140             ADP receptor antagonist      arterial thrombosis            II         >2007         >2007

AZD7009             antiarrhythmic IV            atrial fibrillation -          II         >2007         >2007
                                                 conversion
AZD7009             antiarrhythmic oral          atrial fibrillation -          II         >2007         >2007
                                                 maintenance
AZD9684             CPU inhibitor                thrombosis                      II        >2007         >2007

AZD0837             thrombin inhibitor           thrombosis                      II        >2007         >2007

AZD7806             IBAT inhibitor               dyslipidaemia                   I         >2007         >2007

AZD4619                                          dyslipidaemia                   I         >2007         >2007

AZD6610                                          dyslipidaemia/diabetes          I         >2007         >2007

AZD8294                                          dyslipidaemia                  PC         >2007         >2007

AZD8677                                          dyslipidaemia/diabetes         PC         >2007         >2007

AZD8450                                          dyslipidaemia                  PC         >2007         >2007

AZD6370                                          diabetes                       PC         >2007         >2007

Line Extensions

Atacand                angiotensin II antagonist   CHF outcomes                III        Approved       Filed
                                                   (CHARM study)

Atacand                angiotensin II antagonist   diabetic retinopathy        III         > 2007        >2007

Crestor                statin                      atheroma                    III         2H2006        2H2006

Crestor                statin                      outcomes CHF                III         >2007         >2007

Crestor                statin                      outcomes Renal              III          2007         2007

Seloken/Toprol-XL      beta-blocker                HCTZ combination            III                       3Q2005

Exanta                 thrombin inhibitor          prevention of stroke in     III         Filed        Filed*
                                                   AF

Exanta                 thrombin inhibitor          treatment of VTE            III         Filed         >2007

Exanta                 thrombin inhibitor          arterial/post MI            II          >2007         >2007

* Discussions are ongoing with the FDA to determine if there is now a realistic prospect of bringing Exanta to
the US market. The NDA file remains open.


Gastrointestinal

NCEs

       Compound                  Mechanism                 Area under          Phase         Estimated Filing
                                                          investigation                       MAA          NDA

AZD0865                potassium-competitive acid    acid related GI disease     II          2007          2007
                       blocker (P-CAB).

AZD7371                                              functional GI disease       II          >2007        >2007

AZD3355                inhibitor of transient lower  gastro-oesophageal          I           >2007        >2007
                       oesophageal sphincter         reflux disease (GERD)
                       relaxations  (TLESR)

AZD9343                inhibitor of transient lower  gastro-oesophageal          I           >2007        >2007
                       oesophageal sphincter         reflux disease (GERD)
                       relaxations  (TLESR)

AZD5745                                              acid related GI disease     PC          >2007        >2007

AZD8081                                              functional GI disease       PC          >2007        >2007

Line Extensions

Nexium                 proton pump inhibitor         NSAID GI side effects -    III      Promotable*     Filed
                                                     symptom resolution

Nexium                 proton pump inhibitor         parenteral formulation     III       Launched       Filed

Nexium                 proton pump inhibitor         NSAID GI side effects -    III       Launched      Launched
                                                     ulcer prevention

Nexium                 proton pump inhibitor         NSAID GI side effects -    III       Launched       Filed
                                                     ulcer healing
Nexium                 proton pump inhibitor         extra-oesophageal           II         >2007        >2007
                                                     reflux disease

* Authorities stated these symptoms were already captured within the GERD label.  Text stating 'No clinical
interaction with naproxen or rofecoxib' was approved.

Neuroscience

NCEs

       Compound                  Mechanism                Area under         Phase          Estimated Filing
                                                         investigation                      MAA           NDA

Cerovive                free radical trapping agent  stroke                   III         2H 2006       2H 2006

AZD 7371                                             overactive bladder        II          >2007         >2007

AZD8129 (AR-A2)         5HT1B antagonist             anxiety/depression        II          >2007         >2007

AZD4282                 NMDA antagonist              neuropathic pain          I           >2007         >2007

AZD3102                                              Alzheimer's disease       PC          >2007         >2007

AZD1080                                              Alzheimer's disease       PC          >2007         >2007

AZD9272                                              neuropathic pain          PC          >2007         >2007

AZD2327                                              anxiety                   PC          >2007         >2007

AZD5904                                              multiple sclerosis        PC          >2007         >2007

AZD6538                                              neuropathic pain          PC          >2007         >2007

Line Extensions

Seroquel                D2/5HT2 antagonist           sustained release        III     1H 2006         1H 2006

Seroquel                D2/5HT2 antagonist           bipolar maintenance      III     2007            2007

Seroquel                D2/5HT2 antagonist           bipolar depression       III     2007            1H 2006


Oncology and Infection

NCEs

 Compound                        Mechanism                 Area under         Phase         Estimated Filing
                                                         investigation                      MAA           NDA

Iressa                  EGFR-TK inhibitor            NSCLC                     III       Withdrawn      Launched

ZD6474                  angiogenesis inhibitor       solid tumours              II         >2007         >2007
                        (VEGFR-TKI)

ZD4054                  endothelin A receptor        solid tumours              II         >2007         >2007
                        antagonist

AZD2171                 angiogenesis inhibitor       solid tumours              I          >2007         >2007
                        (VEGFR-TKI)

AZD3409                 farnesyl-transferase         solid tumours              I          >2007         >2007
                        inhibitor
                        ( FAR )

AZD0530                 SRC kinase inhibitor         solid tumours and          I          >2007         >2007
                                                     haematological
                                                     malignancies

AZD5438                 selective cyclin dependent   solid tumours              I          >2007         >2007
                        kinase inhibitor

AZD6244                 MEK  inhibitor               solid tumours              I          >2007         >2007

ZD6126                  vascular targeting agent     solid tumours              PC         >2007         >2007

AZD4440                 vascular targeting agent     solid tumours              PC         >2007         >2007

AZD9935                 angiogenesis inhibitor       solid tumours              PC         >2007         >2007
                        (VEGFR-TKI)

AZD0424                 SRC kinase inhibitor         solid tumours              PC         >2007         >2007

AZD1152                 aurora kinase inhibitor      solid tumours and          PC         >2007         >2007
                                                     haematological
                                                     malignancies

AZD4769                                              solid tumours              PC         >2007         >2007

AZD3841                                              solid tumours              PC         >2007         >2007

AZD8931                                              solid tumours              PC         >2007         >2007

Line Extensions

Merrem                  carbapenem antibiotic        skin and soft tissue      III                       Filed
                                                     infections

Faslodex                oestrogen receptor           1st line advanced         III          >2007        >2007
                        antagonist                   breast cancer

Iressa                  EGFR-TK inhibitor            head & neck cancer*       III        2H 2006       2H 2006

Iressa                  EGFR-TK inhibitor            breast cancer*             II         >2007         >2007

Iressa                  EGFR-TK inhibitor            colorectal cancer*         II         >2007         >2007

* under review


Respiratory and Inflammation

NCEs

 Compound                        Mechanism                 Area under          Phase        Estimated Filing
                                                          investigation                     MAA          NDA
AZD9056                ion channel blocker           rheumatoid arthritis        II        >2007        >2007

AZD9056                ion channel blocker           osteoarthritis              II        >2007        >2007

AZD8309                chemokine receptor antagonist rheumatoid arthritis        I         >2007        >2007

AZD8955                collagenase inhibitor         osteoarthritis              I         >2007        >2007

AZD8309                chemokine receptor antagonist COPD                        I         >2007        >2007

AZD3778                chemokine receptor antagonist asthma / rhinitis           I         >2007        >2007

AZD9056                ion channel blocker           COPD                        I         >2007        >2007

AZD3342                protease inhibitor            COPD                        I         >2007        >2007

AZD6067                protease inhibitor            COPD                        PC        >2007        >2007

AZD2098                                              asthma                      PC        >2007        >2007

AZD1981                                              asthma                      PC        >2007        >2007

AZD0902                ion channel blocker           rheumatoid arthritis        PC        >2007        >2007

AZD6703                                              rheumatoid arthritis        PC        >2007        >2007

AZD6357                                              osteoarthritis              PC        >2007        >2007

AZD7928                                              COPD                        PC        >2007        >2007

AZD2914                                              COPD                        PC        >2007        >2007

AZD2392                                              asthma/rhinitis             PC        >2007        >2007

AZD1744                                              asthma/rhinitis             PC        >2007        >2007

AZD5672                                              rheumatoid arthritis        PC        >2007        >2007

Line Extensions

Symbicort Turbuhaler   inhaled steroid/fast onset,   single therapy for         III       2H 2005
                       long-acting ss2 agonist       asthma

Symbicort pMDI         inhaled steroid/fast onset,   asthma                     III        Filed     2Q/3Q 2005*
                       long-acting ss2 agonist

Symbicort pMDI         inhaled steroid/fast onset,   COPD                       III        Filed        2007
                       long-acting ss2 agonist

*   US development of the Symbicort pMDI is progressing and the Phase III clinical programme in asthma is
complete.  Following a pre-NDA meeting with the FDA in the fourth quarter of 2004, an NDA filing for this
formulation is now targeted for Q2/Q3 2005, although FDA has identified some issues associated with the inhaler
that require the generation of additional chemistry and manufacturing data or possible modification of the
device in order to achieve approval.



AstraZeneca Development Pipeline: Discontinued Projects

6 October 2004 vs. 27 January 2005

Cardiovascular

NCE /Line Extension             Compound               Area under investigation

NCE                              AZD0303                   thrombosis


Gastrointestinal

NCE /Line Extension             Compound               Area under investigation

NCE                             AZD9139                Acid related GI disease


Comments


As disclosure of compound information is balanced by the business need to maintain
confidentiality, information in relation to some compounds listed here has not been disclosed
at this time.


Compounds in development are displayed by phase.


Abbreviations:


PC -  Pre-clinical: Candidate Drug accepted for development but not yet  administered to man.

MAA - Marketing Authorisation Application (Europe)

NDA - New Drug Application (USA)

NCE - New Chemical Entity


                      This information is provided by RNS
            The company news service from the London Stock Exchange